Hematide

PALO ALTO, Calif., Feb 01, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the 12TH Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 4:00 p.m. ET (1:00 p.m. PT). A live webcast of the presentation...

PALO ALTO, Calif., Jan 25, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced completion of treatment and follow-up of patients with anemia due to chronic renal failure enrolled in the four-trial, Phase 3 clinical program for the investigational drug Hematide. The company expects to report topline results fr...

PALO ALTO, Calif., Jan 05, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the 28th Annual JP Morgan Healthcare Conference on Wednesday, January 13, 2010 at 9:00 a.m. PT (12:00 p.m. ET). A live webcast of the present...

PALO ALTO, Calif., Dec 01, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that management will present at the Piper Jaffray 21st Annual Healthcare Conference on Wednesday, December 2, 2009, at 2:00 p.m. ET (11:00 a.m. PT). A live webcast of the presentation will be available on the investors section of ...

PALO ALTO, Calif., Nov 24, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the closing of its underwritten public offering of 4,726,027 shares of its common stock, which includes the full exercise of the underwriter's overallotment option of 616,438 shares. The net proceeds to the company after de...

PALO ALTO, Calif., Nov 19, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it has priced an underwritten public offering of 4,109,589 shares of its common stock at a price of $18.25 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approxi...

PALO ALTO, Calif., Nov 18, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY), today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Affymax expects to grant the underwriters a thirty-day option to purchase additional shares of commo...

PALO ALTO, Calif., Nov 10, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed its final scheduled review and has informed the company that the cumulative safety data generate...

PALO ALTO, Calif., & DEERFIELD, Ill., Nov 04, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide(TM) showing that Hematide increased hemoglobin and reduced or eliminated the need for blood tra...

PALO ALTO, Calif., Nov 04, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008. Affymax recognized revenue for th...

PALO ALTO, Calif., Nov 03, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Hollings C. Renton to the position of chairman of the company's board of directors effective December 1, 2009. Mr. Renton replaces Nick Galakatos, who served as lead board member since the company's initial ...

PALO ALTO, Calif. & DEERFIELD, Ill., Oct 30, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated th...

PALO ALTO, Calif., Oct 22, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego. Affymax's drug, Hematide(TM), is currently in development with Takeda Pharmaceutical Compa...

PALO ALTO, Calif., Sep 25, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it has obtained an issuer managed equity facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity, Ltd. Affymax is not obligated to utilize any of the facility, which has a term ...

PALO ALTO, Calif., Sep 09, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009. The company expects a period of approximately four months for d...

PALO ALTO, Calif., Sep 03, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced the company's participation at the following investor conferences during the month of September. Robert W. Baird & Co. 2009 Health Care Conference Wednesday, September 9, 2009 1:45 p.m. Easte...

PALO ALTO, Calif., Aug 05, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2009. The net loss for the second quarter of 2009 was $22.1 million compared to a net loss of $18.9 million for the second quarter of 2008. Affymax recognized revenue for the ...

PALO ALTO, Calif., Jul 20, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed another review and has informed the company that the cumulative safety data generated thus far f...

PALO ALTO, Calif., Jun 10, 2009 (BUSINESS WIRE) -- Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of Hollings C. Renton to the company's board of directors. Before retiring in 2008, Mr. Renton served as chairman of the board of Onyx Pharmaceuticals, Inc. from 2000, where he also serv...

PALO ALTO, Calif., Jun 03, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed another review and has informed the company that the cumulative safety data generated thus far f...